517 related articles for article (PubMed ID: 25118790)
1. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients.
Schaefer JK; McBane RD; Black DF; Williams LN; Moder KG; Wysokinski WE
Thromb Haemost; 2014 Nov; 112(5):947-50. PubMed ID: 25118790
[TBL] [Abstract][Full Text] [Related]
2. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
3. Novel oral anticoagulants in secondary prevention of stroke.
Diener HC; Easton JD; Hankey GJ; Hart RG
Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
[TBL] [Abstract][Full Text] [Related]
4. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation.
Aryal MR; Ukaigwe A; Pandit A; Karmacharya P; Pradhan R; Mainali NR; Pathak R; Jalota L; Bhandari Y; Donato A
Am J Cardiol; 2014 Aug; 114(4):577-82. PubMed ID: 24998087
[TBL] [Abstract][Full Text] [Related]
6. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Dumont B; Faille D; Ajzenberg N
Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
[TBL] [Abstract][Full Text] [Related]
7. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.
Cohen H; Doré CJ; Clawson S; Hunt BJ; Isenberg D; Khamashta M; Muirhead N;
Lupus; 2015 Sep; 24(10):1087-94. PubMed ID: 25940537
[TBL] [Abstract][Full Text] [Related]
9. The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
Prandoni P; Barbar S; Milan M; Vedovetto V; Pesavento R
Eur J Intern Med; 2014 Jan; 25(1):25-30. PubMed ID: 24120221
[TBL] [Abstract][Full Text] [Related]
10. The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation.
Pfeilschifter W; Luger S; Brunkhorst R; Lindhoff-Last E; Foerch C
Cerebrovasc Dis; 2013; 36(2):115-9. PubMed ID: 24029592
[TBL] [Abstract][Full Text] [Related]
11. [New oral anticoagulants in the treatment of venous thromboembolic disease].
Calvo Romero JM; Lima Rodríguez EM
Semergen; 2013 Apr; 39(3):146-9. PubMed ID: 23540987
[TBL] [Abstract][Full Text] [Related]
12. Novel oral anticoagulants: a review of new agents.
Wanat MA
Postgrad Med; 2013 Jul; 125(4):103-14. PubMed ID: 23933899
[TBL] [Abstract][Full Text] [Related]
13. A review of oral anticoagulants in patients with atrial fibrillation.
Greenspon AJ
Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
[TBL] [Abstract][Full Text] [Related]
14. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome.
Malec K; Góralczyk T; Undas A
Thromb Res; 2017 Apr; 152():93-97. PubMed ID: 27989533
[TBL] [Abstract][Full Text] [Related]
15. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
Gorzelak-Pabiś P; Duraj I; Szlagowska L; Ciastkowska A; Broncel M
Pol Merkur Lekarski; 2014 Nov; 37(221):261-4. PubMed ID: 25546985
[TBL] [Abstract][Full Text] [Related]
17. Disadvantages of VKA and requirements for novel anticoagulants.
Shameem R; Ansell J
Best Pract Res Clin Haematol; 2013 Jun; 26(2):103-14. PubMed ID: 23953899
[TBL] [Abstract][Full Text] [Related]
18. Use of new oral anticoagulants in antiphospholipid syndrome.
Arachchillage DJ; Cohen H
Curr Rheumatol Rep; 2013 Jun; 15(6):331. PubMed ID: 23649961
[TBL] [Abstract][Full Text] [Related]
19. Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians.
Brem E; Koyfman A; Foran M
J Emerg Med; 2013 Jul; 45(1):143-9. PubMed ID: 23375217
[TBL] [Abstract][Full Text] [Related]
20. [New anticoagulants: dabigatran, rivaroxaban and apixaban].
Vargas Ruiz AG; Ramírez López AN; Medina Viramontes ME
Gac Med Mex; 2012; 148(3):257-64. PubMed ID: 22820359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]